Increased risk of VTE w/ increasing age, +ve family history of VTE, obesity (BMI >30 kg/m
2), prolonged immobilization, major surgery, any surgery to the legs or major trauma, superficial thrombophlebitis & varicose veins. Increased risk of arterial thromboembolic complications w/ increasing age, smoking, dyslipoproteinemia, obesity (BMI >30 kg/m
2), HTN, migraine, valvular heart disease, atrial fibrillation, +ve family history of arterial thrombosis. Increased risk of thromboembolism in the puerperium. DM, SLE, hemolytic uremic syndrome, Crohn's disease or ulcerative colitis & sickle-cell disease. Increase in frequency or severity of migraine. Long-term use of combined OCs contributes to this increased risk of cervical cancer; slightly increased relative risk of breast cancer. Discontinue prior to starting therapy w/ the HCV combination drug regimen ombitasvir/paritaprevir/ritonavir w/ or w/o dasabuvir. Women w/ hypertriglyceridemia or family history thereof may be at increased risk of pancreatitis when using combined OCs. Discontinue if a sustained clinically significant HTN develops during use of combined OCs. Jaundice &/or pruritus related to cholestasis; gallstone formation; porphyria; SLEs; haemolytic uraemic syndrome; Sydenham's chorea; herpes gestationis; otosclerosis-related hearing loss; (hereditary) angioedema have been reported w/ COC use. Discontinue if acute or chronic disturbances of liver function occur. Avoid too much exposure to sun or UV radiation for women w/ tendency to chloasma. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Measure BP & perform physical exam prior to therapy. Irregular bleeding may occur during the 1st mth of use. Lactation.
Sign Out
